Dose Group 1 + MN-221 placebo + Dose Group 2 + Dose Group 3

Phase 2Terminated

0 watching 0 views this week⚡ Active

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Asthma

Conditions

Asthma, Status Asthmaticus

Trial Timeline

Jun 1, 2008 → Mar 1, 2009

NCT ID

NCT00683449

About Dose Group 1 + MN-221 placebo + Dose Group 2 + Dose Group 3

Dose Group 1 + MN-221 placebo + Dose Group 2 + Dose Group 3 is a phase 2 stage product being developed by MediciNova for Asthma. The current trial status is terminated. This product is registered under clinical trial identifier NCT00683449. Target conditions include Asthma, Status Asthmaticus.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT00683449	Phase 2	Terminated	Jun 1, 2008	Mar 1, 2009	Asthma

Competing Products

20 competing products in Asthma

See all competitors

Product	Company	Stage	Hype Score
Roflumilast	AstraZeneca	Phase 3	77
Dulera	Merck	Approved	85
Briquilimab	Jasper Therapeutics	Phase 1	25
YHD001 dose level 1 + YHD001 dose level 2 + Singulair + Placebo	Yuhan	Phase 2	52
Roflumilast	AstraZeneca	Phase 3	77
Omalizumab	Daiichi Sankyo	Phase 3	77
Omalizumab	Daiichi Sankyo	Phase 3	77
Tacrolimus Inhalation Aerosol	Astellas Pharma	Phase 2	52
Regadenoson + Placebo	Astellas Pharma	Approved	85
Tacrolimus	Astellas Pharma	Phase 2	52
tacrolimus	Astellas Pharma	Phase 2	52
Zero-dose + 90 mcg of PROAIR® HFA + 180 mcg of 90 mcg of PROAIR® HFA + 90 mcg of albuterol sulfate inhalation aerosol	Sun Pharmaceutical	Phase 3	77
rabeprazole	Eisai	Phase 3	77
KHK4563 + KHK4563 + KHK4563 + Placebo	Kyowa Kirin	Phase 2	52
Placebo + Brodalumab	Kyowa Kirin	Phase 2	52
ONO-6950 + ONO-6950 + Montelukast + Placebo	Ono Pharmaceutical	Phase 2	52
ONO-6950 + Placebo + Montelukast	Ono Pharmaceutical	Phase 2	52
Albuterol Sulfate Inhalation Aerosol (90 mcg per actuation) + Ventolin HFA 90Mcg/Actuation Inhalation Aerosol_#1 + Ventolin HFA, 90 Mcg/Inh Inhalation Aerosol_#2 + Placebo	Cipla	Phase 3	77
Budesonide 80 μg and Formoterol Fumarate Dihydrate 4.5 μg + Symbicort, 80 Mcg-4.5 Mcg/Inh Inhalation Aerosol + Placebo	Cipla	Phase 3	77
90 mcg Reference Product + 180 mcg Reference Product + 90 mcg Test Product + Placebo	Cipla	Phase 3	77

Other Products from MediciNova

MN-166 + placeboPhase 2/3

Ibudilast + Placebo oral capsulePhase 2

MN-166 (50 mg) First + Placebo FirstPhase 2

MN-001 + PlaceboPhase 2

Placebo (for MN-166) + MN-166 + riluzolePhase 2